Leptin-related peptides

• US 20070162987A1
• Filed: 03/05/2007
• Published: 07/12/2007
• Est. Priority Date: 08/21/1998
• Status: Active Grant

• Current Assignee: Albany Medical College (Albany Medical Center)
• Original Assignee: Albany Medical College (Albany Medical Center)
• Inventors: Lee, Daniel, Leinung, Matthew, Grasso, Patricia
• Granted Patent: US 7,786,265 B2
• Time in Patent Office: Days
• US Class Current: 800/14
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2267/0362 Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: C07K 14/5759 Products of obesity genes, e.g. leptin, obese (OB), tub, fat
• CPC Class Codes: G01N 2800/02 Nutritional disorders
• CPC Class Codes: G01N 2800/303 Eating disorders, e.g. anorexia, bulimia
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5088 of vertebrates
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The present invention relates to methods and compositions containing novel leptin peptides, preferably for the modulation of body mass (i.e., weight), more specifically for novel diagnostic and therapeutic applications in homeostasis of body weight and adipose tissue mass.

Claims

1. An isolated nucleic acid comprising a nucleotide sequence encoding any one of the leptin related peptides of SEQ ID NOS:

2-16 and 18, and fragments, derivative, homologs and analogs thereof of those peptides.

2. A vector comprising the nucleic acid of claim 1.

3. A cultured cell that produces a leptin peptide encoded by the nucleic acid of claim 1.

4. The cell of claim 3, wherein the cell is selected from the group consisting of bacteria, yeast, mammalian cells, plant cells and insect cells.

5. A method for preparing a leptin peptide comprising:

(a) culturing a cell containing a nucleic acid according to claim 1 under conditions that provide for expression of the peptide of the invention; and

(b) recovering the expressed peptide.

6. A pharmaceutical composition comprising a nucleic acid of claim 1, wherein the nucleic acid encodes a leptin peptide, and a pharmaceutically acceptable carrier.

9. A kit comprising in one or more containers a leptin peptide encoded by the nucleic acid of claim 1, a nucleic acid according to claim 1, or an antibody that recognizes a leptin peptide according to claim 7.

7. An antibody specific for any one of the peptides of SEQ ID NOS:

2-16 and 18, and fragments, derivatives, homologs, and analogs of said peptides.

8. An antibody of claim 7 labeled with a detectable label.

10. A recombinant non-human animal containing a nucleic acid, wherein the nucleic acid is an isolated nucleic acid comprising a nucleotide sequence encoding any one of the leptin related peptides of SEQ ID NOS:

2-16 and 18, and fragments, derivative, homologs and analogs thereof of those peptides.

11. A method of identifying a drug useful in a weight loss diet regimen comprising:

(a) administering doses of any one or more of the leptin peptides of SEQ ID NO;

2-16 and 18 to a test animal and compare to a placebo control animal over a prescribed time period; and

(b) determining the change in weight of the test animal compared to the control during the prescribed time period;

wherein a peptide that causes the test animal to lose weight relative to the control animal is selected as a drug that is useful in a weight loss diet regimen.

12. A method of identifying a modulator and/or potential modulator of body mass homeostasis in situ comprising:

(a) contacting a cell with the presence or absence of a peptide comprising any one or more of the peptides depicted in SEQ ID NOS;

1-16 and 18;

(b) determining the level of desired effect in cells so contacted compared to cells not so contacted;

wherein

when an increase or decrease in desired effect is determined in the presence of the peptide relative to in the absence of the peptide, the peptide is identified as a potential modulator of body mass homeostasis.